CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题：Monoclonal Antibodies: The Greatest Resource to Treat Multiple Myeloma.
Monoclonal Antibodies: The Greatest Resource to Treat Multiple Myeloma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
多发性骨髓瘤（MM）是一种目前无法治愈的血液系统恶性肿瘤，其特征为髓系细胞和淋巴细胞发生免疫学改变。一线治疗采用传统化疗，但许多患者会复发，并可能进展为难治性MM。新的治疗前沿包括使用新型单克隆抗体（mAb），如daratumumab、isatuximab和elotuzumab。除单克隆抗体外，研究者也在评估基于新型双特异性抗体和CAR-T 细胞的免疫疗法。因此，免疫疗法是治疗MM最有希望的方向。本综述重点介绍已获批或临床应用的新型抗体靶点，包括用于MM治疗的CD38（daratumumab和isatuximab）、SLAMF7（elotuzumab）和BCMA（belantamab mafodotin）。尽管该病仍无法治愈，未来目标是从所有可用药物中找到最佳治疗组合。
Multiple myeloma (MM) is a currently incurable hematologic cancer. This disease is characterized by immunological alterations of myeloid cells and lymphocytes. The first-line therapy involves the use of classic chemotherapy; however, many patients have a relapsed form that could evolve into a refractory MM. The new therapeutic frontiers involve the use of new monoclonal antibodies (Mab) such as daratumumab, isatuximab, and elotuzumab.
In addition to monoclonal antibodies, new immunotherapies based on modern bispecific antibodies and chimeric antigen receptor (CAR) T cell therapy have been investigated. For this reason, immunotherapy represents the greatest hope for the treatment of MM. This review intends to focus the attention on the new approved antibody targets.
The most important are: CD38 (daratumumab and isatuximab), SLAM7 (elotuzumab), and BCMA (belantamab mafodotin) for the treatment of MM currently used in clinical practice. Although the disease is still incurable, the future perspective is to find the best therapeutic combination among all available drugs.
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。
